Biopsychosocial distress and clinical outcome in metastatic renal cell carcinoma. Issue 3 (18th June 2018)

• Record Type: Journal Article
• Authors: Bergerot, Cristiane Decat; Clark, Karen Lynn; Ashing, Kimlin Tam; Bergerot, Paulo Gustavo; Obenchain, Richard; Dizman, Nazli; Hsu, JoAnn; Philip, Errol; Loscalzo, Matthew; Pal, Sumanta Kumar
• Is Part Of: Palliative & supportive care. Volume 17:Issue 3(2019)
• Page Start: 353
• Page End: 355
• Publication Date: 2018-06-18
• Subjects: Kidney cancer, -- metastatic disease, -- distress screening, -- overall survival, -- biopsychosocial distress; Palliative treatment -- Great Britain -- Periodicals; 616.029
• DOI: 10.1017/S1478951518000342
• Languages: English
• ISSNs: 1478-9515

Abstract

Abstract: Objective: Limited research exists examining the biopsychosocial experience of patients diagnosed with metastatic renal cell carcinoma (mRCC), a disease commonly associated with a poor prognosis. The purpose of this study was to describe rates and types of distress in mRCC patients and explore the relationship between distress and overall survival. Method: A cohort of 102 patients with mRCC treated at a single institution was assessed by a touch screen–based instrument comprising 22 core items spanning physical, practical, functional, and emotional domains. Association between biopsychosocial distress and clinicopathologic criteria was interrogated. Overall survival was compared between patients with low distress versus high distress. Result: High rates of distress (20.7%) were found among patients newly diagnosed with mRCC. Among those domains contributing to distress, pain, fatigue, and financial comorbidity were the most commonly reported by patients with mRCC. A trend toward poorer overall survival in those patients with high distress versus low distress was observed among mRCC patients. Significance of results: Based on data from a relatively large sample of patients, this study provides the first specific insights into the potential impact of biopsychosocial distress and outcomes among patients with mRCC.